Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 228

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial

Open access
Shimizu, Wataru, Kubota, Yoshiaki, Hoshika, Yu, Mozawa, Kosuke, Tara, Shuhei, Tokita, Yukichi, Yodogawa, Kenji, Iwasaki, Yu-ki, Yamamoto, Takeshi, Takano, Hitoshi, Tsukada, Yayoi, Asai, Kuniya, Miyamoto, Masaaki, Miyauchi, Yasushi, Kodani, Eitaro, Ishikawa, Masahiro, Maruyama, Mitsunori, Ogano, Michio, Tanabe, Jun, EMBODY trial investigators, Shiomura, Reiko, Fukuizumi, Isamu, Matsuda, Junya, Noma, Satsuki, Sangen, Hideto, Komiyama, Hidenori, Imori, Yoichi, Nakamura, Shunichi, Nakata, Jun, Miyachi, Hideki, Takagi, Gen, Todoroki, Takahiro, Ikeda, Takeshi, Miyakuni, Tomoyo, Shima, Ayaka, Matsushita, Masato, Okazaki, Hirotake, Shirakabe, Akihiro, Kobayashi, Nobuaki, Takano, Masamitsu, Seino, Yoshihiko, Nishi, Yugo, Suzuki, Keishi, Shibuya, Junsuke, Saito, Tsunenori, Nakano, Hiroyuki, Taichirou, Morisawa, Furuse, Erito, Nakama, Kenji, Hosokawa, Yusuke, Tsuboi, Ippei, Kawanaka, Hidekazu · 2020 · Cardiovascular Diabetology

Abstract

Background: Protection from lethal ventricular arrhythmias leading to sudden cardiac death (SCD) is a crucial challenge after acute myocardial infarction (AMI). Cardiac sympathetic and parasympathetic activity can be noninvasively assessed using heart rate variability (HRV) and heart rate turbulence (HRT). The EMBODY trial was designed to determine whether the Sodium–glucose cotransporter 2 (SGLT2) inhibitor improves cardiac nerve activity. Methods: This prospective, multicenter, randomized, double-blind, placebo-controlled trial included patients with AMI and type 2 diabetes mellitus (T2DM) in Japan; 105 patients were randomized (1:1) to receive once-daily 10-mg empagliflozin or placebo. The primary endpoints were changes in HRV, e.g., the standard deviation of all 5-min mean normal RR intervals (SDANN) and the low-frequency–to–high-frequency (LF/HF) ratio from baseline to 24 weeks. Secondary endpoints were changes in other sudden cardiac death (SCD) surrogate markers such as HRT. Results: Overall, 96 patients were included (46, empagliflozin group; 50, placebo group). The changes in SDANN were + 11.6 and + 9.1 ms in the empagliflozin (P = 0.02) and placebo groups (P = 0.06), respectively. Change in LF/HF ratio was – 0.57 and – 0.17 in the empagliflozin (P = 0.01) and placebo groups (P = 0.43), respectively. Significant improvement was noted in HRT only in the empagliflozin group (P = 0.01). Whereas intergroup comparison on HRV and HRT showed no significant difference between the empagliflozin and placebo groups. Compared with the placebo group, the empagliflozin group showed significant decreases in body weight, systolic blood pressure, and uric acid. In the empagliflozin group, no adverse events were observed. Conclusions: This is the first randomized clinical data to evaluate the effect of empagliflozin on cardiac sympathetic and parasympathetic activity in patients with T2DM and AMI. Early SGLT2 inhibitor administration in AMI patients with T2DM might be effective in improving cardiac nerve activity without any adverse events. Trial Registration: The EMBODY trial was registered by the UMIN in November 2017 (ID: 000030158). UMIN000030158; https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000034442 .

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12933-020-01127-z

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 228

Metadata

Authors
Shimizu, W., Kubota, Y., Hoshika, Y., Mozawa, K., Tara, S., Tokita, Y., Yodogawa, K., Iwasaki, Y.-K., Yamamoto, T., Takano, H., Tsukada, Y., Asai, K., Miyamoto, M., Miyauchi, Y., Kodani, E., Ishikawa, M., Maruyama, M., Ogano, M., Tanabe, J., EMBODY trial investigators, Shiomura, R., Fukuizumi, I., Matsuda, J., Noma, S., Sangen, H., Komiyama, H., Imori, Y., Nakamura, S., Nakata, J., Miyachi, H., Takagi, G., Todoroki, T., Ikeda, T., Miyakuni, T., Shima, A., Matsushita, M., Okazaki, H., Shirakabe, A., Kobayashi, N., Takano, M., Seino, Y., Nishi, Y., Suzuki, K., Shibuya, J., Saito, T., Nakano, H., Taichirou, M., Furuse, E., Nakama, K., Hosokawa, Y., Tsuboi, I., & Kawanaka, H.
Venue
Cardiovascular Diabetology
Published
2020-09-25
Volume
19
Issue
1
Pages
148-148
ISSN
1475-2840 (ISSN-L)
OpenAlex
W3088460171
Cited by
228
References
13
FWCI
17.67
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial. https://app.cochat.ai/papers/10.1186/s12933-020-01127-z
The paper
Shimizu, W., Kubota, Y., Hoshika, Y., Mozawa, K., Tara, S., Tokita, Y., Yodogawa, K., Iwasaki, Y.-K., Yamamoto, T., Takano, H., Tsukada, Y., Asai, K., Miyamoto, M., Miyauchi, Y., Kodani, E., Ishikawa, M., Maruyama, M., Ogano, M., Tanabe, J., . . . Kawanaka, H. (2020). Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial. Cardiovascular Diabetology. https://doi.org/10.1186/s12933-020-01127-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.